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If words were colors, cancer would be black.
Fortunately, it doesn’t have to be like that. At Children’s Mercy, we’re dedicated to bringing color into children’s
and families’ lives.
Our cancer program is one of the best in the country in outcomes and, we believe, it is the best in terms of our
dedicated and compassionate staff and our first-rate, child-friendly facilities.
It would be unrealistic to publish the stories of the nearly 2,000 children with cancer and blood diseases we
serve each year; but a few are included in this report and their stories represent all of our children. The stories
share some common themes:

One step at a time
Despite the odds
Fear

Randall L. O’Donnell, PhD
President and CEO
Children’s Mercy

One of the family
And my personal favorite: All grown up.
We’ve also included highlights from some of the programs that distinguish us from other hospitals: the
Cytogenetics Laboratory where we see how a person’s genetic makeup can determine the best cancer
treatment; our Hispanic Oncology Clinic, designed to best serve our growing patient base in their natural
language; Radiation Oncology, a critical tool in helping shrink some tumors; and the Experimental
Therapeutics in Cancer Program that in just its fourth year is at the forefront of making cancer medications
safer and more effective for children.
At the center of all our work is a dedication to children and their families. We treat nearly 90 percent of all
newly diagnosed pediatric cancers in our region, and our outcomes rank among the best in the nation. We
can’t do this all ourselves so we strive for excellence with our partners like the University of Missouri – Kansas
City, the KU Cancer Center and more.
We do all of this to transform lives. Lives of children with cancer. Lives of parents and siblings who don’t know
what hit them. Our lives are changed, too.
And the sun comes up each day, colors emerge and brightness overcomes the dark at Children’s Mercy.
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Dear Colleagues,
It is my great pleasure to introduce this year’s
Children’s Mercy Cancer Center Annual Report that
focuses on one of our largest patient groups —
children with brain tumors.
At Children’s Mercy, between one-fifth and onefourth of our patients in any given year come to us
with a diagnosis of a brain tumor. As you’ll read,
the types of brain tumors afflicting children are quite
varied and relatively rare and, as such, need welltrained and experienced providers.
Children with brain tumors require a vast array
of specialty services and experienced clinicians
to provide and oversee their care from the time
of diagnosis to their long-term follow-up and
transition to adult providers. We are fortunate to be
able to provide to our region just such a team of
highly trained, highly skilled and highly experienced
providers of care for children with brain tumors.
Led by Kevin Ginn, MD, a board-certified Pediatric
Oncologist with advanced subspecialty training in
Neuro-Oncology, our Brain Tumor Team consists
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of board-certified pediatric specialists in Oncology,
Neurology, Neurosurgery, Rehabilitation Medicine,
Radiation Therapy, Developmental Medicine,
Neuro-Pathology, Neuro-Radiology, Bone Marrow
Transplantation and Neuro-Psychology. Adding to
this team of providers are highly trained individuals
from the pediatric disciplines of nursing, pharmacy,
nutrition, social work, education, child life and
chaplaincy who are solely dedicated to the care of
these patients.
Under the direction of Dr. Ginn and the team of
23 Pediatric Hematology/Oncology specialists at
Children’s Mercy, our unique case management
system teams an advanced nurse practitioner with
each physician to individually oversee each child’s
therapeutic course and long-term followup. Utilizing
a dedicated Hem/Onc clinic/outpatient infusion
center and a 38-bed hepafiltered Hem/Onc floor,
our patients have 24/7 inpatient and outpatient
specialist coverage delivering the latest therapies,
including access to clinical trials from the National
Cancer Institute’s (NCI’s) Children’s Oncology Group

and other pediatric research consortiums, including
new experimental agents in conjunction with our
Phase I Experimental Therapeutics Program at
Children’s Mercy.
Each child diagnosed with a brain tumor, and
in the care of our team, undergoes thorough
review, including discussion among all the team’s
specialists at twice-monthly Brain Tumor Patient
Conferences. Engaging these specialists on the
team and the full spectrum of Pediatric medical and
surgical specialists at Children’s Mercy ensures that
every child receives the best therapy possible.
I invite you to read on and see for yourself the full
array of services and the resulting improvement in
outcomes for our patients.

Alan S. Gamis, MD, MPH
Associate Division Director, Division of Hematology/
Oncology/BMT
Chief, Section of Oncology

Dear Friends and Colleagues,
It is with great pleasure that we present the 2012
Cancer Care Annual Report from Children’s Mercy
Cancer Center with a focus on Central Nervous
System Tumors. It is hard to believe that a year has
passed since my return to Children’s Mercy from
Neuro-Oncology training at St. Jude. As you may
know, I accepted a faculty position after training in
Hematology/Oncology at Children’s Mercy. My goal
was to develop a formalized pediatric brain tumor
program after my return from Memphis. I felt right
at home here at Children’s Mercy from day one and
was excited to have this opportunity to develop an
important program with the support of the hospital
administration and faculty.
This is an exciting time in Pediatric Neuro-Oncology.
Neurosurgical techniques and equipment have
improved over the decades leading to more complete
resections. Complete resection is important in
almost all CNS tumors. Targeted agents are being
expedited to clinical trials through high-throughput
screening of agents already available on the market.
Molecular profiling of large collections of tumors is
leading to more information regarding not only cells
of origin or new targets, but also better grouping of

patients based on genetic risk. Some of the work in
medulloblastoma has shown us that the molecular
profiling of these patients can better predict outcome
than the traditional risk stratification methods still
in use. Advances made in radiation delivery and
planning have reduced the exposure of normal
tissue to the detrimental effects of radiation. Proton
beam radiation centers continue to be built across
the country with the hope that this modality has the
same outcome as traditional radiation while reducing
toxicity to normal tissues. Long-term studies are still
lacking to determine if this is, in fact, the case.
Through all of these advances, which are most
importantly aimed to increase the survival of patients,
care continues to be placed on the morbidity
associated with therapy. What benefit have we
provided a patient who survives if they are so
devastated by the therapy involved that they are
unable to function adequately in society?
This report focuses on all tumors seen at Children’s
Mercy during 2012 with a more broad focus on
CNS tumors seen over a decade. Also, you will find
descriptions of the multidisciplinary approach to

CNS tumors here at Children’s Mercy and how each
department plays an important role in the care of
every patient. Finally, we focus on other exciting
programs and advances in our Division to keep you
up-to-date on what is happening here.
Looking back over the past year, I think my first year
should be themed, “Building a Team.” All of the
components were already present here at Children’s
Mercy and patients have always received excellent
care, but now there is a specific group of care
providers who have dedicated themselves to play an
active role in the care of patients with CNS tumors.
We meet regularly to discuss care and ensure our
patients are getting the best possible therapy. Now
as we move forward, we will focus on strengthening
ties to local and international groups to increase our
research base and bring more and more cutting
edge therapy to the children of the Kansas City region.

Kevin F. Ginn, MD
Pediatric Neuro-Oncology
Director, Pediatric Brian Tumor Program
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Division of Hematology,
Oncology and Bone
Marrow Transplantation
Each year, the Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation (BMT)
provides comprehensive care to nearly 2,000 children with childhood cancers, sickle cell disease,
hemophilia and other blood disorders. Our team of more than 20 pediatric hematology/oncology
specialists offers a level of expertise unavailable anywhere else between St. Louis and Denver, caring
for 90 percent of newly diagnosed cases in our region each year. Plus, our role in several national
research consortia helps make sure patients have access to the most recent advances in treatment. Our
innovative research and comprehensive approach to care has led to survival rates at or above national
averages for nearly every category of disease.
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Working with the Center for Pediatric Genomic Medicine at Children’s Mercy, we are at the forefront of research to
better understand the genetic causes of cancer and translate that research into treatment that can improve care.

We are a
comprehensive
pediatric cancer
center offering 13
clinical and researchfocused multispecialty
programs.

We offer aggressive treatment
options for adolescent and young
adult patients, as well as follow-up
care and support to address the
long-term health and psychosocial
needs of these patients.

In 2012, we once again
received accreditation
from the American College
of Surgeons Commission
on Cancer.

Our Experimental
Therapeutics in
Pediatric Cancer
program, working
with our internationally
recognized Clinical
Pharmacology
program, is helping
make cancer
medications safer
and more effective
for children here and
around the world.

Patients have direct access to more than 80
clinical trials — including several national
trials led by our own investigators, as well as
trials through the National Cancer Institute’s
Children’s Oncology Group and several
other national research consortia.
Our pediatric bone marrow transplantation
program is a regional center for Missouri,
Kansas and Iowa, performing 35
transplants a year, including unrelated and
related donor transplants for both malignant
and non-malignant diseases.

We are the primary pediatric cancer provider and only NCI Children’s Oncology Group institution in the Midwest Cancer Alliance,
which links the NCI designated University of Kansas Cancer Center with member hospitals to advance cancer research and care.
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Cancer Registry
The Cancer Registry at Children’s Mercy operates
under the direction of the Cancer Care Committee. All
patients who are diagnosed or treated at Children’s
Mercy with a malignancy or a benign brain tumor
are included in the cancer registry database. In
the United States, hospital-based registries are
the foundation of cancer surveillance. The primary
goal of these registries is to improve patient care by
evaluation of treatment outcomes. Data collected
by the cancer registry may be used for physician
education, research and facility utilization review. All
data about the diagnosis, treatment, recurrence and
survival must be collected in standardized detail.
At Children’s Mercy, the cancer program maintains
accreditation from the American College of Surgeon’s
Commission on Cancer. As an accredited program
the high quality standards of the Commission on
Cancer, as well as other organizations they endorse,
are followed in the data collection process.
During 2012, there were 183 new patients added
to the cancer registry database. Of the 183 new
registered patients, there were 44 who were
diagnosed with central nervous system tumors,
which is the focus of this annual report. CNS tumors
were followed closely with 42 leukemia diagnoses.
There were 17 patients who were considered benign
reportable conditions. These patients were requested
to be collected by the Cancer Care Committee for
8

surveillance purposes. Please see the frequency of
diagnosis table for further disease breakdown.
The median age of patients diagnosed during 2012
is 12 years. There were 25 patients less than 1 year of
age diagnosed in 2012. The 1-4 year old age group
consisted of 63 patients, the 5-9 year old age group
had 42 patients, the 10-14 year old age group had 33
patients, and there were 20 patients in the 15-19 year
old age group. There were 94 male patients and 89
female patients during 2012.
Race distribution included 156 Caucasians, 18 African
Americans, and 9 designated as other race. Of the
Caucasian patients, 25 were of Spanish/Hispanic
ethnicity.

During 2012 the patients who were entered into the
registry database came from five different states and
57 different counties. Fifty one percent of the patients
were from Kansas, 47 percent from Missouri and 2
percent from other states.
These patients will be followed in the coming years by
the registry as were all of our previous patients. After
treatment, if all Children’s Mercy visits are curtailed,
the registry will use other methods for follow-up.
Strict patient confidentiality guidelines are followed
according to HIPAA privacy regulations.

All CNS - 2003-2009
Excluding Benign Tumors

FREQUENCY OF DIAGNOSIS-2012
		

Diagnosis

Central Nervous System
Astrocytoma
Glioma
Medulloblastoma
Ependymoma
Atypical Teratoid Rhabdoid
Gliobastoma Multiforme
Meningioma, Papillary
PNET
Choroid Plexus Carcinoma
Benign Borderline CNS
Leukemia
ALL
AML
JMML
CML
Lymphoma
Non-Hodkgins
Hodgkins
Neuroblastoma
Ganglioneuroblastoma
Neuroblastoma
Wilms Tumor
Hepatoblastoma
Rhahbdomyosarcoma
Retinoblastoma
Ewings
Osteosarcoma
Germ Cell Tumor
Langerhan’s Cell Histiocytosis
Melanoma
Sarcoma
Clear Cell Sarcoma of Kidney
Epithelioid Sarcoma
Undifferentiated emryonal
Undifferentiated
Other Malignant
Peripheral Nerve Sheath Tumor
Medullary Carcinoma of Thyroid
Myelodysplastic Syndrome
Benign Reportable Conditions
Teratoma
TMD/TAM- Transient Myeloproliferative
Disorder / Transient Abnormal
Myelopoiesis
Plexiform Neurofibroma
Hemangioendothelioma
Ganglioneuroma
Hemophagocytic Lymphohistiocytosis
		

TOTAL

Totals
44
7
7
5
3
2
2
1
1
1
15
42
32
7
2
1
12
6
6
19
4
15
8
6
5
4
4
3
3
5
3
4
1
1
1
1
4
1
1
2
17
9

Percentage
24

Frequency of CNS
Tumors/2003-2012
23

7

10

4
3
3
2
2
2
2
3
2
2

2

9

2
2
1
2
1

183

100

5 YEAR RELATIVE SURVIVAL RATES FOR CNS TUMORS
NATIONAL / CHILDREN’S MERCY COMPARISONS
1995-2009 / Age 0-19
HISTOLOGY

Astrocytoma- NOS,
diffuse, fibrillary
Pilocytic Astrocytoma
Anaplastic Astrocytoma

ICD-0 Code

CBTRUS (1995-2009)
Central Brain Tumor Registry
of the United States

CM (1995-2009)
Children’s Mercy

9400/3, 9410/3, 9411/3,
9420/3

83.2

88.3 (n=43)

9421/3

96.8

96.6 (n=90)

9401/3

31.2

25.0 (n=4)

Ependymoma - NOS,
Anaplastic & Papillary

9391/3, 9392/3,
9393/3

73.8

61.6 (n=28)

GlioblastomaMultiforme, Giant Cell

9440/3, 9441/3

18.2

16.6 (n=6)

Glioma malignant, NOS
& Mixed

9380/3, 9382/3

59.0

Embryonal TumorsMedulloblastoma
(all variants),
PNET (Primitive
neuroectodermal
tumor), ATRT (Atypical
teratoid/rhabdoid
tumor)

71.4 (n=63)
51.2 (n=37 Excluding
optic nerve site)

9470/3
9471/3
9473/3
9474/3
9508/3

61.9

56.8 (n=77)

Germ Cell of CNSGerminoma & Mixed
Germ Cell

9064/3
9085/3
(2003-2009 data)

90.1

92.3 (n=13)
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Brain Tumors
Central Nervous System tumors are the second most common type of tumor seen in pediatric patients after leukemia. We have seen
significant improvements in survival rates for patients with leukemia over the last few decades, and although neuro-oncology has also seen
some improvement, we have not made as many advances. We are currently on the cusp of a new era in biological understanding that will
lead to better risk stratification, more targeted therapy and an improvement in survival rates, while decreasing the associated morbidity of
patients with CNS tumors.
The National Cancer Institute collects cancer data
representing 28 percent of the U.S. population to
report incidence, prevalence and survival of cancer in
the Surveillance Epidemiology and End Results (SEER)
reports. From 1975 through 1977 they reported a 58.9
percent five-year relative survival of CNS tumors in
patients aged 0-19 years. From 2003 to 2009 this
same population had a five-year relative survival
of 75.1 percent showing a statistically significant
improvement in survival in three decades.
Established in 2002 the Central Brain Tumor Registry
of the United States collects data on benign and
malignant CNS tumor from state registries and
estimates the incidence of a CNS tumor in the U.S.
for patients 0-19 years of age is 5.13 per 100,000
with 3.3 per 100,000 being malignant cases. They
estimate that 4,300 new pediatric CNS tumors will be
diagnosed in the United States in 2013.

At Children’s Mercy we see approximately 40 new
patients each year with CNS tumors and closely
monitor our survival data compared to national
statistics to ensure we are providing state of the art
care.
We will now provide general information and
updates on the three most common types of CNS
tumors seen in pediatrics, which together account for
up to 80 percent of the CNS tumors we treat.

Low Grade Gliomas
Low grade gliomas are the most common type of
CNS tumor encountered in a pediatric patient with
approximately 50 percent of patients falling into this
category. Low grade gliomas are a group of tumors
that are classified as World Health Organization
Grade I or II depending on pathological features and
can occur anywhere throughout the central nervous
system. They commonly appear in the spinal cord,

optic nerve or optic pathway, and in the posterior
fossa/cerebellar region. Dissemination is rare and
is estimated to be present in only 2 to 3 percent of
patients at diagnosis. Complete surgical resection
remains the therapy of choice for these tumors and
if achieved is considered curative. Patients who are
fortunate enough to have a gross total resection only
require close follow-up imaging to ensure there is
no recurrence. Recurrence happens in about 10 to
20 percent of cases after complete resection, and
if identified, second surgical resection should be
the first consideration, likely followed by additional
therapy. As these are slow growing tumors that often
are surgically resected, the survival is very good at
greater than 90 percent five-year overall survival.
In patients where gross total resection is not possible,
the therapy choices are limited to radiation or
chemotherapy and the physician must consider
each carefully depending on multiple factors.
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Chemotherapy has become standard first-line
therapy in those patients where it is desirable to
avoid radiation either due to patient age, or due to
the location of the tumor making long-term radiation
effects concerning. Carboplatin and Vincristine are
now considered standard first-line chemotherapy
and is continued for approximately one year or until
progression. The five-year progress free survival
with this regimen as investigated on the COG A9952
clinical trial was 35 percent. After progression, there
are several other chemotherapy regimens available
and most result in only stability of disease rather
than reduction in tumor volume, if effective at all.
Although radiation is often more effective, the neurocognitive and neuro-endocrine long-term effects are
undesirable. It has been reported that the five-year
progress free survival with chemotherapy alone is
38 percent and with radiation plus chemotherapy is
68 percent. In those patients who are older with a
low grade glioma, especially those tumors in a lower
risk location, or tumors in patients with progression
after multiple chemotherapy approaches, radiation is
recommended.
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For patients with Neurofibromatosis (NF1), who have a
predisposition to low grade gliomas due to mutations
in neurofibromin, radiation is avoided if at all possible
no matter the age of the patient due to their higher
risk of secondary malignancy and vascular effects
post radiation. About 15 percent of patients with
Neurofibromatosis will have an optic pathway
glioma with a pilocytic astrocytoma histology. Low
grade gliomas in Neurofibromatosis patients,
for poorly understood reasons, are often slower
growing or remain stable and have been reported to
spontaneously regress. More understanding of these
observed differences could shed light on biological
activity of low grade gliomas in general.
Most of the current research in low grade gliomas
has been related to understanding and targeting
receptor tyrosine kinase pathways thought to play a
critical role in development of these tumors. In 2008
a duplication of a section of chromosome 7 was
identified in a majority of pilocytic astrocytomas. Later
this duplication was found to result in fusion between
KIAA1549 and BRAF leading to constitutive activation
and is reported in 50 to 100 percent of tumors.
Upstream of BRAF, RAS activation can also lead to
increased signaling through the PI3K/AKT/mTOR

pathway. Loss of neurofibromin in Neurofibromatosis
leads to less inhibition of Ras, and thus, increased
signaling. Targeting any portion of this pathway is
desirable for low grade gliomas, as well as other
types of cancer, and research is ongoing with preclinical as well as clinical trials underway.

Medulloblastoma
Medulloblastoma is the second most common CNS
tumor in pediatric patients but is often quoted as the
“most common malignant brain tumor of pediatrics”
as low grade gliomas are often referred to as
“benign.” Medulloblastoma accounts for 20 percent
of CNS tumors and the peak age is 4 years. These
tumors by definition are posterior fossa/cerebellar
tumors previously referred to as infratentorial primitive
neuroectodermal tumors. Approximately 25 percent
of patients have metastatic disease within the central
nervous system at diagnosis and less than 5 percent
have spread outside of the central nervous system.
Historically we know that older patients who have
a complete resection who do not have metastatic
disease and who are treated with craniospinal
radiation and chemotherapy have the best survival
rate. Five-year overall survival in these patients is

reported at around 85 percent. Those patients who
have metastatic disease fair much worse with fiveyear survival reported in the 30 to 40 percent range.
In patients with recurrent disease multiple options
are available, but very few patients survive. We need

more therapy options for those patients with high-risk
disease at diagnosis as well as those unfortunate
enough to have a recurrence after initial aggressive
therapy.
Current therapy protocols risk stratify patients

COMMON CNS TUMORS - 2003-2012
5 Yr. Overall Relative Survival
100
90
80

40

There have been significant improvements in our
understanding of medulloblastoma since 2006 when
early molecular subgrouping started being reported.
The most recent published consensus regarding this
work has recommended four molecular subgroups of
medulloblastoma: WNT, SHH, Group 3 and Group 4.

30

•

70
Percent Survival

based on age, metastatic disease, residual tumor
and diffuse anaplastic histology. Efforts in infants
to avoid radiation have resulted in very intensive
chemotherapy administration and most are treated
with three courses of high dose chemotherapy with
autologous stem cell rescue after three courses of
induction chemotherapy. Patients older than 3 years
of age proceed to standard therapy with immediate
craniospinal radiation with posterior fossa boost
and often a year of chemotherapy afterward. These
patients may be cured of their disease but are often
left with many issues, including neuro-cognitive
deficits, neuro-endocrine deficits and hearing loss.

60

Low Grade Glioma- n=66 , OS-98%
Medulloblastoma- n=36, OS-71.2%

50

Ependymoma- n=24, OS- 64.5%

20
10
0

Ependymoma
Low Grade Glioma
Medulloblastoma

0

1

2
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Years
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The WNT subgroup includes most often young
patients who are rarely metastatic at diagnosis
with very good prognosis with current therapy.
Most discussions in the field regarding the WNT
subgroup are related to how we might reduce
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prognostic genetic finding. This group, as well
as Group 4, have no common pathway that can
be targeted like the SHH and WNT groups and
will be more difficult to determine the next best
approach to improving outcomes.

therapy, maintaining the excellent outcomes, and
thus reduce subsequent morbidity. A reduction
in radiation dose or even eliminating radiation
altogether is the most appealing area for
reducing therapeutic intensity.
•

•
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The SHH subgroup is most commonly seen
in the very young and adult patients. They are
uncommonly metastatic and have a good
prognosis in infants and intermediate prognosis
in other patients. They are defined by mutations
in the SHH pathway with frequent changes seen
in PTCH1/SMO/SUFU, GLI2 or MYCN. There are
targeted inhibitors of this pathway available on
the market such as the Smoothened inhibitor
Vismodegib (GDC-0449) but most studies have
shown a dramatic but temporary response to
this agent alone. Work is on-going with agents to
target this pathway and learn what may lead to
escape from inhibition.
Group 3 consists of tumors found most
commonly in children and are more commonly
metastatic at diagnosis with the worse prognosis
of any of the other groups. They very frequently
have MYC amplification, which is a poor

•

Group 4 consists of an intermediate risk group
that frequently has metastatic disease, but not
as frequently as seen in Group 3. Again, this is
a group that is difficult to easily define and will
require much more investigation to better define
individual targets.

The field of Pediatric Neuro-Oncology has been
inspired by this work classifying medulloblastoma. It
has been shown that molecular subgrouping better
defines prognosis than the traditional risk stratification
currently in use. Upcoming clinical trials will focus
on grouping these patients based on this data and
intensifying or reducing therapy based on their
predicted outcomes. Targeted therapy is the wave
of the future in oncology, although much work still
needs to be done and it is unlikely that a single target
without additional intensive and traditional therapy
approaches will be successful in this disease.

Medulloblastoma is the
second most common CNS
tumor in pediatric patients.

Ependymoma
Ependymomas are the third most common
malignant central nervous system tumor in
pediatrics accounting for approximately 10 percent
of tumors. They arise from the ependymal cell layer
of the ventricles or central canal of the spinal cord.
Intracranial ependymomas are more common in
those patients less than 4 years of age while spinal
cord tumors are more common in those patients
older than 10 years. Ependymomas are divided by
the World Health Organization into three grades
with Grade III, or anaplastic ependymoma, having
the worst outcomes. Therapy is determined by the
grade, location, age and extent of resection. Surgical
resection has been shown to affect prognosis most
significantly and if possible should be aggressively
pursued in these patients. This has to, of course, be
balanced with a desire not to harm the patient and
leave them with devastating neurological deficits after
surgery.
The only known genetic syndrome associated with
increased risk of ependymoma is Neurofibromatosis
type 2 (NF2), and those patients most often present
with spinal cord tumors. Work is ongoing to

investigate genomic profiles and targets that may
lead to improved stratification for therapy and new
therapeutic agents.
In current clinical trials for ependymoma researchers
are investigating effectiveness of chemotherapy
as well as safety of avoiding any therapy in lowgrade tumors with complete surgical resection.
Many centers are already carefully watching
patients with Grade I and Grade II tumors without
any further therapy. Many others still consider
radiation after surgery to be the standard, and
current studies may answer this question and
allow more children to avoid radiation. Patients
with Grade III tumors are most often treated with a
combination of chemotherapy and radiation, but
even some of these patients have been observed if
complete resection was achieved. For the youngest
patients, avoiding radiation is always the goal, and
intensive chemotherapy regimens are administered
for this reason. Ependymoma is sensitive to
chemotherapy, but less than half of infants treated
with chemotherapy alone ultimately avoid radiation
as they experience progression or relapse of disease.

Ependymomas are the third
most common malignant
central nervous system tumor
in pediatrics accounting for
approximately 10 percent of
tumors.
15

Katelin’s Courage: Recovering
from Cancer, One Step at a Time
When 11-year-old Katelin Pittillo, of Garden City, Kan., began experiencing neck pain
and weakness in her left arm, her mother, Mandi Pittillo, thought it was the result of a
motorcycle accident she had been in a year earlier.
But when her symptoms continued to worsen, Katelin
was referred to Christian Kaufman, MD, a pediatric
neurosurgeon with Children’s Mercy. That’s when Katelin
and her mom received the diagnosis that would change
her life: she had an extremely rare type of cancer called
spinal ependymoma.
“Katelin had a grade II spinal cord tumor about four
inches long and shaped like a hot dog in the middle of
her spinal cord,” describes Kevin Ginn, MD, the pediatric
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neuro-oncologist who oversaw her care. “It started at the
base of her brain and extended down her neck.”

First Things First
For Katelin and her medical team, the first priority was
to get rid of the tumor — immediately. “This surgery is a
very delicate balance between trying to remove all of the
tumor while protecting her function,” Dr. Ginn says.
During an 11-and-one-half hour operation, Dr. Kaufman
removed 90 percent of the growth. But it was wrapped
around the sensitive nerves that control Katelin’s motor

Rehabilitation Medicine

functions, and in spite of careful monitoring, she lost
most of the function in her left arm and leg.

Rehabilitation is often needed for patients with brain and spinal cord tumors, either due to the
direct effects of the tumor on the function of normal tissue, or due to the morbidity associated with
surgical removal of the tumor and other complications that may arise. Dr. Kimberly Hartman
is an active member of the Neuro-Oncology Team and works with a team of specialists to improve
function of those patients with neurological deficits. The Rehabilitation Team provides a collaborative
model of care for children who have a change in their ability to perform everyday activities as a
result of a brain or spinal cord tumor.

Taking the Next Step

Whether a child has difficulty with mobility, self-care, cognition or overall strength and endurance,
we develop a therapeutic plan to emphasize independence and return of function. This plan
may involve different therapeutic disciplines (physical therapy, occupational therapy and speechlanguage pathology), equipment, assistive technologies, modalities and medications to help a child
return to their favorite activities. As a child’s needs change, our team is able to adapt and provide
the appropriate support to maintain the highest quality of life for our patients and families.
For children undergoing surgery or treatment in the hospital, we offer an acute, intensive inpatient
rehabilitation program to maximize functional recovery. Depending on the needs of the child and
family, we also work closely with therapists in the community, as well as in the home, to provide the
most appropriate level of individualized care.
The rehabilitation medicine team consists of the only board-certified pediatric physiatrists in the
region, nurse practitioners, nurses, nurse coordinators, pediatric-trained physical and occupational
therapists, speech-language pathologists, music therapists, and child life specialists. Our mission
is to partner with families and other specialists to empower children with different abilities to lead
extraordinary lives.

Katelin’s complicated case benefited from the team
approach Children’s Mercy offers. In addition to
Drs. Kaufman and Ginn, Kimberly Hartman, MD, a
specialist in physical medicine and rehabilitation,
prescribed physical therapy to help Katelin regain
the use of her left arm and leg.
“Following surgery, Katelin couldn’t even take
one step,” Dr. Ginn says. That made the need for
rehabilitation even more critical. Once she recovered
from surgery, she was transferred to the hospital’s
inpatient rehabilitation unit where she quickly began
the hard work necessary to walk again.
After spending 48 days in Children’s Mercy, she was
ready for the next step on her journey — continued
rehabilitation as an outpatient at the Rehabilitation
Institute of Kansas City; and radiation therapy at the

Above and left: Dr. Kimberly Hartman
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Kansas City Cancer Center to treat the remaining
tumor in her spine.

Radiation Therapy

There’s No Place Like Home

Many patients with brain tumors need radiation therapy and here at Children’s Mercy we
collaborate with Vickie Massey, MD, from the University of Kansas Cancer Center. She is board
certified in Radiation Oncology and is a member of the Children’s Oncology Group with many years
of experience treating pediatric patients.

Almost three months after making the 377-mile trip
to Children’s Mercy, Katelin returned home. She had
completed 27 radiation therapy treatments and
intensive rehabilitation. Today she continues her
physical therapy in Garden City and attends classes
online until she is strong enough to return to the sixth
grade.
“She took 40 steps with a walker on Oct. 3,” Mandi
says. “The connections are there. She just needs to
re-train and re-strengthen her left side. She’s made
remarkable progress.”
Though the road to recovery is a long one, Mandi is
grateful for her daughter’s positive attitude and her
outstanding health care team at Children’s Mercy.
“This was a very scary situation, but through it all,
Katelin has kept her chin up and kept fighting,”
Mandi says. “Everyone at Children’s Mercy took a
genuine interest in her case. We were so far from
home for so long, we couldn’t have made it back
here without them.”
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Radiation therapy has been a standard treatment modality for brain tumors for many years.
Radiation therapy gives patients the option to have their tumors treated when invasive surgery isn’t
possible or is not enough to control the tumor. Many significant advances in imaging, radiation
therapy and radiosurgery techniques have occurred recently, leading to improved delivery
precision. This results in fewer acute and late effects. Treatment may include the whole brain, or
most often, only a limited area. In all cases, the role of treatment is determined by the age of the
patient, the diagnosis and areas of involvement, or the behavior of the tumor type.
Treatment is tailored for each patient to allow optimal control of the tumor, while preserving the
most normal tissue. Our team approach to management is vital, as combined modality treatment
is frequently employed, and the timing and dosing of therapy is critical. Patients come Monday
through Friday, with therapy going on for several weeks. Some patients may be candidates for
radiosurgery, which delivers higher doses of radiation in one to five treatment sessions. Because
some of our children are so young, and unable to cooperate, we depend on the Children’s Mercy
anesthesiology team to deliver the most accurate therapy. Children’s Mercy has partnered with the
University of Kansas Cancer Center and the Midwest Gamma Knife Center at Research Medical
Center to offer treatment options locally. Arrangements can be made to utilize national resources as
needed.

Vickie Massey, MD

Radiation Oncology

Vickie Massey, MD, is one of just a few pediatric
radiation oncologists in the country, and the only
active one in the Children’s Oncology Group in the
Kansas City region. Her role is critical in treating the
cancer tumor patients she regularly sees.

A critical component to performing her job as a
radiation oncologist comes from assistance through
the anesthesia team at Children’s Mercy, Dr. Massey
said. The staff has a special touch in comforting the
patient to create a calm environment.

“Brain tumors are one of the most common tumors
we see at Children’s Mercy,” she said.

“It’s a complete approach,” she said. “All the support
teams are what makes Children’s Mercy such a
remarkable hospital. Everyone collaborates so well.”

Of the 183 newly diagnosed patients Children’s Mercy
treated in 2012, 44 of those patients were diagnosed
with brain tumors. The number of cases is consistent
with national figures, as brain tumors are noted as
the most common solid tumors for children, according
to the National Cancer Institute.
One therapy for brain tumors is radiation, which is
used to attempt to shrink the malignant growths. The
department treats an average of about 50 patients
annually and nearly a dozen have brain tumors. The
length of treatment for patients is about four to seven
weeks and the success rate is dependent on the type
of cancer, with the most favorable at 80 percent or
more, Dr. Massey said.

Children’s Mercy oncologists will make the diagnosis.
A team of oncologists, nurse case managers,
therapists and social workers meet with the patients
and parents for a planning session as to how to
proceed with treatment. Dr. Massey meets with
other oncology members and participates in patient
conferences
“We have a pretty involved staff,” Dr. Massey said.
Because of her unique position of having a specialty
without nearby peers she finds assistance from
a national network of pediatric oncologists who
offer advice and tips about cases from their own
experiences. They share data and clinical questions.  

“I’m able to discuss cases with the national radiation
oncology members and have multiple places where
I can turn,” Dr. Massey said. “They are so generous
with their time.”
Massey decided on the field of radiation oncology
because of her own personal experience when her
father had brain cancer. She was a medical student
at the time and her father was only in his 40s. Her
medical school mentor suggested a rotation with a
radiation oncologist. The experience solidified her
decision to make it her specialty. She finished her
training at Memorial Sloan-Kettering Cancer Center.
“It’s a very obscure field and that’s how I learned
about it,” she said of her father’s illness.
“In a treatment area where the latest equipment and
techniques set the pace for therapy improvements,
it’s important to keep connections at a human level,”
Dr. Massey said. “We have a lot of machines, and
technology is going to continue to improve our
delivery, but in the end there is a patient.”
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Hailey’s Come-back
Nothing seemed to soothe 17-month-old
Hailey Phegley of Independence, Mo.
during September of 2012.
She hardly moved or played, slept a
lot and was often upset.
Her mother, Tricia Phegley, took her to the doctor
who prescribed medication for a double ear
infection.
Phegley waited for the antibiotics to take effect,
but several days later Hailey still showed no
improvement. In fact, her condition worsened.
“She started throwing up instead of getting
better,” Tricia Phegley said.
They returned to the doctor and left with a
stronger prescription.
But there was still no change. Hailey’s appetite
disappeared. She started losing her balance and
running into doors. She couldn’t sit upright on a
couch without falling over. The vomiting became
more frequent and her hazel-colored eyes started
crossing.
“She only wanted to sleep or be held,” Tricia Phegley
said.
Although Hailey was nearly 18 months old, she had not
started walking.
“There were no other symptoms and we just agreed she
was a late walker,” Tricia said. “But now looking back,
there was a brain tumor growing.”
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Finding the Problem
In late September of 2012 Tricia took Hailey to the eye
doctor to see what might be causing the eye crossing.
An exam with eye dilation revealed optic nerve
swelling on both eyes.
“They said that means there’s pressure in the brain and
they sent us to the ER immediately,” she said.
A CT scan at the emergency room showed a tumor at
the back of her head.

Ophthalmology

“We just thought she needed glasses. We weren’t
thinking she had a brain tumor,” Hailey’s mom said.

The pediatric ophthalmologists at Children’s Mercy
are active members of the team caring for patients
with brain tumors. There are six full-time pediatric
ophthalmologists at Children’s Mercy who provide
specialized examinations to look for early signs
and subtle changes in the eyes of children affected
by brain tumors.

Occasionally, a brain tumor will be first suspected
and subsequently diagnosed after a routine eye
exam. Unexplained vision loss, new misalignment
of the eyes or headache will often bring a patient
to the eye doctor. Patients are then referred for
neuroimaging if there are concerning findings
during the eye exam.

The eye is one of the few organs in the body
where you can simply look inside and gather
valuable information. This non-invasive
examination can provide details about a child’s
overall condition that greatly assist in decisionmaking about their cancer care. For example, a
look at the back of the eye can track increases or
decreases in intracranial pressure by mapping
changes in swelling around the optic nerve.
Checking visual acuity can look for radiation
damage and give a “status report” for the eye.

Following a diagnosis of a brain tumor, and during
the treatment phase, the ophthalmologist will
then follow the resolution of these symptoms and
remain in close communication with the oncology
team.

Abnormalities in the nerves and muscles that
coordinate eye movement can also be caused
by brain tumors. Changes in the alignment of the
eyes such as new crossing or the inability to move
an eye in a certain direction can be very helpful in
localizing tumors.

Another important function of the ophthalmologist
within the brain tumor team is to monitor slow
growing intracranial tumors such as gliomas
and meningiomas. Frequent eye exams in these
patients, especially at very young ages can help
to signal when aggressive versus conservative
treatments can be employed. A subtle change of
vision in a 2-year-old with neurofibromatosis can
prompt the oncology team to search for an optic
nerve glioma. By closely monitoring these patients
with eye exams in clinic, the need for multiple
sedations for neuroimaging can be reduced.

From the emergency room, they sent her to Children’s
Mercy, where doctors put her in intensive care
immediately to watch her blood pressure, which kept
spiking, and put a drain in her head.
Doctors at Children’s Mercy recommended surgery to
remove the tumor.
Hailey spent time under the care of the Neurosurgery
section where Christian Kaufman, MD and Gregory
Hornig, MD, were her surgeons.
“It was very surreal, very emotional,” Tricia Phegley said.
“At that point they were just concerned with getting
the tumor out. It was a huge relief that they were
able to get it all and she didn’t have any bleeding or
complication.”
The operation also took nearly half the time – six hours
– than the 10 to 12 hours that Tricia Phegley and Hailey’s
dad, Dustin Phegley, had expected.
After pathology revealed a grade IV malignant
medulloblastoma, three courses of chemotherapy,
a stem cell harvest and three courses of high-dose
chemotherapy followed by a stem cell rescue for each
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was then recommended. The chemotherapy was intense
but meant to treat her tumor while avoiding radiation due
to her young age.
Kevin Ginn, MD, was Hailey’s primary oncology doctor.
“He always made time to see and keep tabs on her,” Tricia
Phegley said. “He made sure we understood what to do
about her and her treatment plan.”

On the Way to Recovery
Dr. Ginn quickly asked Dr. Mohamed Radhi from the Bone
Marrow Transplant Team to assist in Hailey’s care. Dr.
Ginn would administer the initial chemotherapy and then
Hailey transitioned to the Team that specializes in high
dose chemotherapy with stem cell rescue to intensify her
therapy.
“The experience with the nurses and doctors was
amazing and they took such good care of Hailey,” Tricia
Phegley said. “No matter where we were, they took
exceptional care of her. The nurses on 4 Henson Tower
treated us like family.”

Moving Beyond
A year later, Hailey is in remission. She loves the color
purple, playing with her stuffed monkeys and dolls, and
with her older sister, Xandi. She likes dancing and gets
excited about Minnie Mouse and the Care Bears.
A few setbacks from the high dosages of chemotherapy
are now behind her and she has learned to walk, feed
herself and adjust to life wearing hearing aids because of
some hearing loss caused by the chemotherapy.
The experience also had a positive effect on Tricia’s future
and she is taking classes to pursue a health care career.
“Being around Children’s Mercy staff made me want to be
a nurse,” she said.
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Radiology
Diagnostic radiology plays an important role in the care of the child with a brain tumor, which
extends from the time of initial diagnosis through the continued monitoring of therapy. Imaging at the
time of initial diagnosis allows for therapeutic planning and more precise intraoperative guidance for
the surgeon.
Diagnostic imaging can effectively show tumor response to therapy and may suggest early
recurrence during the monitoring of therapy. Commonly employed neuroimaging modalities
include magnetic resonance imaging (MRI), computerized tomography (CT) and positron emission
tomography (PET).
More advanced neuroimaging techniques, which may be performed at Children’s Mercy, include
perfusion imaging, tractography and functional MRI (fMRI). Advanced techniques such as these
may also be utilized to guide therapy and improve patient outcomes. Although pediatric radiology
examinations commonly require sedation, sedation can be avoided by utilizing our child life
specialists or by watching a movie with DVD goggles during the scan to help the child feel more
comfortable.
The ultimate goal of diagnostic radiology in the care of a child with a brain tumor is to provide the
highest quality imaging for the diagnosis and treatment of brain tumors in an environment that is
favorable for both the child and family.

Stem Cell Transplant Team

At Children’s Mercy, the stem cell transplant
team works in close coordination with the
Neuro-Oncolgy Team for brain tumor patients
who may benefit from high dose chemotherapy
with autologous stem cell rescue. After referral
to the Stem Cell Transplant Team, the NeuroOncology Team continues to follow very closely in
collaboration to ensure the coordination of care
and therapy planning is optimized for each patient.
The assigned Transplant physician becomes
an integral part of the multidisciplinary team
consisting of the Neuro-Oncologist, Radiation
Oncologist, Neurosurgeon and other supportive
staff to provide the highest level of clinical care.
The outcome for children with malignant
brain tumors has improved in recent years,
especially for those children with ‘standard-risk’
medulloblastoma and other primitive neuroectodermal tumors. For other children with newly
diagnosed malignant brain tumors, especially
in the absence of radical surgical resection, the
outcome remains poor despite surgery, irradiation
and conventional chemotherapy. Patients whose

tumors recur despite initial therapy continue
to experience a dismal outlook with these
conventional strategies of treatment. In an attempt
to improve the outcome for brain tumor patients
with poor prognoses, strategies utilizing high-dose
(potentially myeloablative) chemotherapy with
autologous stem cell rescue have been developed
since the 1970s. Brain tumors are protected from
systemic chemotherapy by the blood-brain barrier
(BBB) and by intrinsic properties of the tumors.
Steep dose–response curves of the cytotoxic
alkylating agents exists, and when used in the
myeloablative regimens might overcome the
blood–brain barrier thereby improving penetrance
of the tumor by cytocidal drugs.
Advances in hematopoietic progenitor stem cell
apheresis and rescue with peripheral blood
progenitor cells or bone marrow (BM), and the
availability of hematopoietic cytokines, have
provided an opportunity to intensify doses of
chemotherapeutic agents. With hematopoietic
progenitor cell rescue, patients are able to tolerate
repeat doses in shorter intervals, even after

craniospinal irradiation. These studies, conducted
initially in patients with recurrent tumors, were
then extended to patients with newly diagnosed
malignant gliomas and brain-stem tumors, as
well as to young children with various malignant
brain tumors at diagnosis in an attempt to avoid
irradiation to the brain. The results of several of these
studies demonstrate durable disease-free survival
for a proportion of patients with recurrent malignant
gliomas and medulloblastomas/PNET, as well as
encouraging data in some of those patients with
newly diagnosed brain tumors.
Intensive chemotherapy with stem cell support has
shown promise but is associated with significant
toxicity. Tandem stem cell rescue schedules,
often used in infants with CNS tumors, permit
administration of increased dose intensity (greater
cumulative doses per unit of time) with potentially
better therapeutic ratio, but concerns remain about
the toxicity of this regimen. Currently many clinical
trials are testing the efficacy of tandem transplants
for various brain tumors in children.

Above: Dr. Mohamed Radhi
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Neurosurgery

Neurosurgery is most often the first point of
contact for a new patient with a brain or spinal
cord tumor. After imaging has been obtained
due to concerning symptoms and a tumor found,
neurosurgery determines the best course of action
for the patient. Immediate procedures may be
needed for stabilizing the patient but another
focus of surgery is to obtain tissue for accurate
diagnosis. There have been great improvements in
neurosurgical techniques, such as image guidance
and microsurgical equipment, and it is thought that
this advancement has been one of the main drivers
to improved survival in pediatric neuro-oncology.
The neurosurgical team works in close collaboration
with multiple services at Children’s Mercy. Because
of this collaboration we can provide optimal services
for the children afflicted with brain tumors; the
process begins at the time of admission, continues
for the duration of treatment, and extends through
long-term follow-up for many years as needed by
the patient.
There are four neurosurgeons on staff and they are
supported by three neurosurgery nurse practitioners,
multiple clinic and floor nurses, and of course
anesthesiology and other operating room staff.
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The Neurosurgeons are all involved in the Brain
Tumor Program planning and development and
participate in the multidisciplinary patient-focused
conferences to determine the safest approach for
best outcomes for each patient. Gregory Hornig,
MD, also provides coordination of care for those
patients who need gamma knife radiosurgery at
the Midwest Gamma Knife Center at Research
Medical Center.
As an example the collaboration needed to care
for a patient, we can look at the actual recent
treatment provided to a 12-year-old patient with
an astroblastoma.
The diagnosis of a brain tumor was made in
2007 on the basis of imaging done with our
Radiology Department. Surgery was assisted with
a navigational device based on images provided
by the Radiologists. Expert ICU physician care and
comprehensive nursing support was provided
post-operatively. Follow-up MRI demonstrated
complete surgical resection. Pathology made
the diagnosis of astroblastoma, a relatively
rare tumor. Our pathologists collaborated
with outside reviewers to ensure an accurate
diagnosis was made. The Oncology Team made

a recommendation for radiation therapy with our
radiation oncologist, based on the final diagnosis.
After tumor recurrence, further surgery was
needed and chemotherapy initiated by Oncology.
Further support was provided by Endocrinology
and Neurology for treatment of diabetes
and seizures. The young lady, who remains
normal neurologically, did not need the help of
Rehabilitation, but such care was available as
needed.
Administration was helpful in providing financial
support and arranging insurance protection with
outside providers.
The Neuro-Oncology Team will be following this
young lady for an indeterminate period of time
with continued monitoring of therapy related
toxicity and recurrence with regular screening
tests and labs and frequent MRI. Eventually she
may transition to the Survive and Thrive Team for
long-term follow-up and transition to adult care.

Above: Drs. John Clough, Gregory Hornig,
Usiakimi Igbaseimokumo and Christian Kaufman

Pathology

Children’s Mercy has state of the art knowledge and laboratory equipment to provide answers to a large spectrum of diagnostic challenges.

Above: Dr. Eugenio Taboada

The pathologist is another key member of the NeuroOncology Team, and Eugenio Taboada, MD, a
member of the Neuro-Oncology Team, works with a
group of pathologists to ensure the best information
is available for therapeutic decisions.

presents the diagnosis and disease findings of
particular patients, which is an essential part of
the discussion and evaluation of patient’s care. A
network of expert opinions locally, nationally or even
internationally is also readily accessible if needed.

A pathologist is the physician (MD or DO) that
specializes in the diagnosis of diseases by different
laboratory methods. By examining the tumor tissue
under the microscope the pathologist provides the
diagnostic classification (the name and type) of brain
tumors. Such information is one essential piece of
the puzzle in planning adequate treatment, and an
estimate of the prognosis or probable outcomes and
probable behavior of the tumor or disease.

The pathologist also works with a group of
laboratory professionals providing answers
and important information using state-ofthe-art diagnostic technologies such as
immunohistochemical, molecular genetics and other
laboratory methods. Children’s Mercy has state of
the art knowledge and laboratory equipment to
provide answers to a large spectrum of diagnostic
challenges.

The pathologist participates in the multidisciplinary
conference: Neuro-Oncology Tumor Board. In this
conference the involved professionals of different
clinical and patient care disciplines of the hospital
get together to present and discuss diagnosis,
management and treatment challenges posed by a
patient with cancer or brain tumor. The pathologist

The results of the diagnostic information are utilized
by the oncologist and Patient Care Clinical Team to
decide the most appropriate treatment and clinical
plan for a particular patient. Thus, the participation
of the pathologists and laboratory professionals
in patient care continues to be essential in current
times.
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Alicia’s Adversity:
Overcoming JPA Despite All Odds
When Shelley’s seven-year-old daughter, Alicia, began experiencing severe neck and
shoulder pain, lethargy and vomiting, Shelley knew something was wrong.
Visits with several pediatricians yielded ineffective
treatments and inaccurate diagnoses, all of which ended
in Alicia not getting better.

days later, a phone call delivered Shelley terrifying news:
her daughter had a brain tumor.

“I took her to several doctors, but none of them could
figure out what was wrong
with her,” said Shelley of
Tonganoxie, Kan. “One
doctor said it was just
allergies.”

“The doctor told me to take her to Children’s Mercy
immediately,” Shelley said. “She didn’t even offer me a
choice because I don’t think there was any question in her
mind where the best place for Alicia to go was.”

Dissatisfied with the
diagnoses, Shelley tried
a new pediatrician who
ordered an MRI. Two

Plan of action

Alicia was admitted and prepped for brain surgery in a
matter of days.
“I was so scared when I first came to the hospital,” Alicia
said. “I remember my mom was allowed to come in the
operating room and stay with me until I fell asleep and that
meant a lot to me.”
“Alicia had a juvenile pilocytic astrocytoma (JPA) of her
cerebellum, the back part of the brain that controls
coordination,” said Maxine Hetherington, MD, Pediatric
Hematologist/Oncologist at Children’s Mercy. “Most JPAs
are easily removed with surgery, but her tumor was
atypical and much more difficult to control.”
Despite all odds, Alicia survived the surgery. However, she
was in a coma for six weeks and lost all of her motor skills.
“No one knew if I could understand them,” Alicia said. “It
was frustrating not being able to communicate. I couldn’t
even blink my eyes.”
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Survive and Thrive
After the completion of therapy for a brain tumor, patients are initially followed closely by their
primary treatment team. After at least two years of being off therapy, patients may then transfer to
the Children’s Mercy Survive and Thrive Clinic. The patient’s history, including diagnosis and previous
therapies, is closely analyzed to determine what each individual patient’s long-term risks are, then a
plan is developed for close monitoring.
The Survive and Thrive clinic is a multidisciplinary clinic that monitors for late effects of cancer
therapy and promotes a healthy lifestyle to prevent development of late effects. Approximately
three out of four childhood cancer survivors develop one or more health problems and 25 percent
of these complications may be severe or life threatening. During a clinic visit each patient and
their family meets with a nutritionist, social worker, nurse educator and physician. Clinic visits are
coordinated so patients also obtain screening studies such as hearing tests on the same day.
This year we have also added a combined clinic with endocrinology, which allows families to
follow-up on previously identified endocrinopathies or to obtain screening for the development of
additional hormone deficiencies. Patients who have received treatment for a brain tumor are at high
risk of developing a hormone deficiency due to the location of their tumor, treatment with radiation,
and/or surgery. Providing this coordination decreases the burden of travel and time away from
work/school on the families.

Above: Children’s Mercy employees and their
families at the 2013 CureSearch Walk

She continued, “I remember my mom and the doctors
were around my bed talking about my cat and a tear
rolled down my eye. That’s when they knew I could
hear.”

One Step at a Time
As Alicia recovered, she began physical therapy at
the hospital.
“The therapists at Children’s Mercy were great,” Alicia
said. “They gave me tools to help me communicate
better and made me more comfortable.”
When Alicia moved her finger for the first time, there
was a huge celebration.
But despite all her progress, it was unlikely Alicia
would be able to walk or talk again.

Resolve to Defy the Odds
“I knew I was going to prove them wrong,” Alicia said.
“I was determined I was going to walk again.”
Over the next five years, Alicia attended physical
therapy sessions at the Rehabilitation Institute of
Kansas City. At the same time, she underwent
chemotherapy, radiation and steroid treatments at
Children’s Mercy.

27

Throughout the course of her treatment and therapy,
Alicia had six reoccurrences of her brain tumor and they
required three additional brain surgeries.
Now recovered and leading a very normal life, Shelley
said she owes Alicia’s life to Children’s Mercy. “We’re
extremely lucky Alicia was here at Children’s Mercy,”
she said. “In all the years she was here, we never felt
the need to go elsewhere for a second opinion.”

Saying Goodbye
Today, 23-year-old Alicia lives with minimal physical
limitations.
She is now a part of the Survive and Thrive program
at Children’s Mercy and is preparing to manage her
own health as she transitions to an adult health care
provider.
Alicia is pursuing a degree in elementary education
from the University of St. Mary in Leavenworth and
recently passed her entry exam for the school’s
teaching program.
Although it’s hard for Alicia to say goodbye to Children’s
Mercy, it’s easy for her to say thank you.
“Children’s Mercy changed my life,” she said, holding
back tears. “It’s just a great hospital. I already miss
Children’s Mercy.”

Still Part of the Mercy Family
Alicia may have ended her time at Children’s Mercy
as a patient, but she is only beginning her time as a
hospital volunteer.
Alicia’s mother, who is already a volunteer, said she’s
excited they can volunteer together—to give back to the
hospital that forever changed their lives.
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Dr. Julia Broussard

Endocrinology
Children diagnosed with brain tumors are
at high risk for multiple endocrinopathies
due to their cancer treatment which is often
a combination of surgery, radiation and
chemotherapy. For example, patients who had
cranial radiation are at high risk for growth
hormone deficiency, delayed or early puberty,
infertility, hypothyroidism, adrenal insufficiency,
compromised bone health and obesity.
In fact, endocrine abnormalities are the most
common late-effects seen in the long-term
follow-up of childhood cancer survivors. That
is why Division of Endocrinology developed a
focused clinic for these patients – the Endocrine
Disorders in Cancer Survivors clinic (EDICS Clinic)
run by Sripriya Raman, MD and Julia Broussard,
MD.
Since the establishment of the brain tumor
program, referral of high-risk patients to
endocrinology has been streamlined and
made seamless. All patients coming through
the EDICS Clinic are risk stratified based on their
comprehensive cancer treatment summary,
educated on their current endocrinopathies

and future risks, treated, and followed closely
as needed. Difficult patient situations are
discussed either informally between members
of the brain tumor team or formally through
regularly scheduled case conferences. Every
effort is made to ensure smooth planned
transition of older patients from pediatric
endocrinologists to adult providers.
Our quarterly EDICS Transition Clinics began
in October 2013. Soon we will start our EDICS
Telemedicine Clinic, which is aimed to minimize
the barriers of distance for patients who live
far away from our hospital with the help
of the exciting and growing technology of
telemedicine.
It is clear that, in the years to come, the brain
tumor team will continue to grow strong and
effective in delivering excellent clinical care
and nurture significant projects addressing
important research gaps. Overall, as an integral
part of the brain tumor team, we take pride in
working hard to improve the standard of care
for these patients and families.

Nursing

Nurses play a vital role in the care of pediatric
patients with brain tumors at Children’s Mercy. The
Neuro-Oncology Clinic has a dedicated nurse who
has a specific interest in caring for patients with
brain tumors, but there are many oncology trained
nurses who help care for our patients. The nurses
in clinic obtain labs, perform initial assessments,
administer chemotherapy and medications, and
provide important teaching to the patients and their
families. Our patients develop strong, supportive
relationships with their nurse who is an important
part of the care team.

On 4 Henson, the Hematology-Oncology floor
in the hospital, the inpatient nurses are also
specially trained to provide care in oncology and
they perform many similar functions that clinic
nurses perform, but 24 hours a day. The patients
on the floor can be critically ill at times or can
be post stem cell rescue, requiring much closer
monitoring.
There are also nurses throughout the hospital
who are important in the care of our patients
in areas such as Radiology, where they assist
with the various procedures needed by the
brain tumor patients. These nurses can include
the sedation nurses, who help sedate patients
for scans such as MRI and CT scans. There
are also nurses in the Interventional Radiology
Department who assist the radiologists with
placement of central lines or gastrostomy tubes,
which are very important in the treatment of
some of our patients.
Finally, there is a dedicated nurse practitioner
within the Neuro-Oncology program. The
nurse practitioner works as a case manager to

coordinate the care of brain tumor patients. This
includes coordinating appointments with multiple
departments such as neurosurgery, radiation
oncology, ophthalmology, endocrinology,
rehabilitation and audiology. The nurse
practitioner also provides extensive teaching for
families and is available to families by phone
during the week when parents have questions
or concerns. The nurse practitioner sees patients
at their normally scheduled clinic visits, and sees
patients urgently when they become ill. The
nurse practitioner also helps with authorizations
with insurance companies and arranging home
health. After normal business hours and on
weekends, a nurse practitioner is always on call
to provide 24-hour support to our patients.
Nurses are involved with brain tumor patients
from initial diagnosis through treatment and even
after treatments are completed. A nurse is even
involved in managing our Long-Term Follow-Up
Clinic where brain tumor patients are seen once
their chemotherapy is completed to manage
long-term complications.
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Family Care Team (FaCT)

Multidisciplinary care is integral to the overall outcomes and well being of our patients. Outside of cancer directed care, families and
patients have many other needs that are often addressed by our Family Care Team. Regular FaCT Team Rounds ensure that all disciplines
involved communicate patient needs and provide support to our families.
Child Life Specialists help make the hospital
more comfortable, easier to understand, and fun for
patients and families. Child Life tries to reduce the
stress and worry that may come with being in the
hospital, or from being ill, by preparing patients and
families for upcoming procedures and helps them
through the procedures using distraction, comfort
positioning and empowering the patients by giving
them realistic choices when available. Child Life also
helps children cope with their feelings, thoughts and
questions, as well as learn and grow while still in the
hospital through normal developmental play and
medical play.
Ten clinical social workers are a part of the
primary team working with patients and their families
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in the Division of Hematology and Oncology at
Children’sMercy. There is a specific clinical social
worker, Caroline Bearden, who is part of the NeuroOncology team. The social workers understand that
any change in a child’s health can alter a family’s
life in many ways. Social workers are licensed
professionals trained to address the needs of the
patient and their family. Social workers help with
therapeutic support including adjustment to illness,
bereavement, crisis intervention, parent child
interactions and sibling support. Care planning
including education on advanced directives, school
issues, legal issues and transition to adult care are
addressed as well. Finally, social workers can help
with community referrals to assist with financial
concerns, transportation issues and mental health

referrals. The social workers help the family develop
coping skills from the point of diagnosis through the
end of treatment and beyond.
Music therapy services are offered to patients and
families at bedside to address the specific needs of
each individual. Music interventions are designed
and planned after an assessment of need and
generally involve the use of both live vocal and
instrumental music. Children are encouraged to take
an active role in making music.
The Parent to Parent Program works hard to
continue providing support services for our families.
There are many programs offered through the
PTP program, including: trained parent mentors
available to share, listen and support our current

parents; a stocked parent room that offers weekly
dinners, breakfasts, therapeutic activities and a safe
place to unwind while a child is inpatient on 4H; and
“care packages” for the new families shortly upon
admission to help ease some burden of a hospital
stay.
The Hematolgy/Oncology/Bone Marrow
Transplantation chaplain is available to meet every
new patient and their family, who are inpatient and
introduce them to chaplaincy services offered at
Children’s Mercy. The family’s own clergy will be
contacted if requested. Chaplains can also assist with
locating a local clergy person of their denomination
or faith if the family is from out of town. The chaplain
continues to support families throughout treatment.

Two psychologists assist with the mental health
challenges that present when under treatment for a
brain tumor. They are available to meet individually
with the patients and their families. The psychologists
complete neurocognitive testing to aid patients in
making sure their education needs are met. They also
monitor the effects of therapy on cognition over time.
One school teacher is onsite to assist patients on the
inpatient unit and outpatient clinic with the challenge
of keeping up with school work while undergoing
treatment. Our school teacher is able to communicate
directly with the child’s school to receive current
assignments and to advocate for the patient’s needs
once they return to the school setting.
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Terrie Flatt, DO		

Spanish Clinic

Terrie Flatt, DO, was studying in Mexico when he
became ill with a parasitic infection and went
looking for care at a rural clinic. It was early in his
education, which focused on the Spanish language
and anthropology, when he discovered and the
communication barrier created a stressful situation as
he sought treatment.
“You don’t know what it’s like until you have been in a
health care situation and do not speak the language,”
said Dr. Flatt, who has lived in Latin America and
Mexico and taught Spanish at the university level for
10 years. “When I decided to go to medical school,
that experience stuck in my mind,” he said. “I can only
imagine what it is like when it is really significant. My
experience was nothing compared to what these
children go through.”
With that experience prominent in his memories, Dr.
Flatt helped to form the Children’s Mercy Spanish-
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Speaking Hematology/Oncology Clinic, which opened
in the summer of 2012. Its mission is to better address
the health needs of the region’s Spanish-speaking
community.
The clinic weaves Dr. Flatt’s medical training with
his background in anthropology and Spanish. Prior
to Children’s Mercy, Dr. Flatt lived in south Texas
where most care givers and patients/families spoke
Spanish. He noticed that Spanish-speaking patients
seemed more easily to assimilate into the medical
environment.
When he came to Children’s Mercy he discovered a
need for that access to bilingual caregivers.
“I said ‘this is an opportunity to help people,’ ” Dr. Flatt
said. “There are so many levels of understanding
and this allows a doctor to have a relationship with
the patient that you can’t have through an interpreter
alone.”

Dr. Flatt has started a system that provides patients
with medication information in English and Spanish
so the patient and any other physician would know
what the patient has been prescribed. “That way I
know with certainty that there won’t be a breakdown
in language that could hinder medical care in
complex patients,” he said.
The population of Spanish-speaking families at
Children’s Mercy mirrors the demographics of
Kansas City at 10 to 15 percent. In 2012, four patients
with brain tumors were of Spanish/Hispanic origin,
according to the Children’s Mercy Medical Records
department.
“For me it’s about communication,” Dr. Flatt said.
“That’s a large diversity of people and establishing
a meaningful relationship and acknowledging the
differences toward health helps patient’s physical,
emotional and spiritual well-being.”

Dr. Flatt’s goals for the clinic include expanding a
telemedicine outreach effort and creating a support
group for Spanish speakers.
“We are striving to increase the outreach to rural
areas for Hispanic consultation and working with
general practitioners,” Dr. Flatt said. “We are forming
parent groups for cancer patients and their families
so they can get together with social workers and
other professionals, and families can voice the
obstacles they face in seeking medical care. We will
also provide general educational support.”
Dr. Flatt’s research in children’s leukemia is also
targeting this population. He will use the samples
from local Hispanic patients who agree to participate
while reaching out to other research sites in the
United States and in Mexico.

“We are in the process of establishing a relationship
with a children’s hospital in Mexico,” he said. “We are
looking for genetic differences in the leukemia cells as
related to ethnicity.”
The project is in the development phase.
“The ultimate goal of a project like this, which will
take years to achieve, is to determine if patients with
certain genetic rearrangements may need more
intense therapy, or perhaps we may find a targeted
drug for some of these genetic alterations,” he
said. “The hope is to have better cure rates for this
population.”
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Linda D. Cooley, MD, MBA
Linda Cooley, MD, MBA, and personnel at the
Cytogenetics Laboratory see daily how a person’s
genetic makeup can determine the best cancer
treatment.

have fragments of DNA attached. The DNA fragments
are designed to match normal pieces of DNA in the
genome. On the chip we are using, there are 2.7
million pieces of DNA on the glass.”

Dr. Cooley’s lab is an accredited clinical testing
laboratory that uses microarray technology from
Affymetrix to look at a patient’s genes and find clues
as to how to best handle their disease. A typical test
for interpreting the genome comes from a small
blood sample, from which the DNA from the blood is
isolated, fragmented and labeled.

An analysis can indicate differences in genetic
material and mutations that can mean risk of
disease.

“The Affymetrix HD Cytoscan makes it possible to
screen the entire genome for variations or changes,”
Dr. Cooley said. “The system has the capability of
detecting different kinds of genetic variations by using
differently designed ‘chips,’ small pieces of glass that
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Cytogenetics

“The newer microarray technologies (like Affymetrix)
allow us to see a lot more of the details of the
genome,” Dr. Cooley said. “In cancers with certain
abnormalities of genes, drugs can be designed to
specifically target the abnormality. By knowing the
genetic makeup and what’s happened we can create
drugs to target abnormalities and have a much better
rate of response and higher cure rate.”

“With the Affymetrix system, we are initiating testing of
different kinds of samples, (bone marrow, tissues and
tumors), with the goal of detecting and characterizing
variations in the DNA of various types of cancer,” Dr.
Cooley said.

or the genetic material can have an affect on how
an individual’s body uses a certain drug. The same
drug might work quickly or effectively in one person,
but may work slowly or not work well for another
person. By examining the DNA for variations, there
is the possibility of identifying why one ethnic group
fairs better than another ethnic group treated with the
same drug therapy.”

In the larger scope of population genetics, application
of this new technology may be used to indicate and
treat certain diseases in populations and ethnic
groups.

The lab purchased the Affymetrix HD Cytoscan
System with funds donated to the Hematology/
Oncology/Bone Marrow Transplantation division from
last year’s annual Big Slick Celebrity Event.

The newfound abundance of genetic information is
now being employed to advance therapies.

Above: Actors Rob Riggle, Paul Rudd
and Jason Sudeikis returned to Kansas
City for the annual Big Slick Celebrity
Event, which benefits Children’s Mercy.
The lab purchased the Affyetrix HD
Cytoscan System with funds donated
to the Hematology/Oncology/Bone
Marrow Transplantation division from
last year’s event.

“We inherit our genes from our ancestors and
depending on what part of the world we come
from, there will be some minor differences in the
DNA,” Dr. Cooley said. “Minor differences in a gene
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Kathleen Neville, MD, MS		
It’s been only four years since the Experimental
Therapeutics in Pediatric Cancer Program began
at Children’s Mercy, but the program has already
exceeded expectations, according to Director
Kathleen A. Neville, MD, MS.

of treating brain tumors. Trials specifically for brain
tumors are an area that we will continually build.
We’re very happy to have a dedicated brain tumor
program, as many brain tumors are a challenge to
treat.”

“The reception by the community has been
phenomenal,” said Dr. Neville, who is board certified
in hematology/oncology and pharmacology. “We’ve
already exceeded our five-year goals.”

The program collaborates locally with the Institute
for Advancing Medical Innovation at the University of
Kansas and consortia from across the country and
North America.

Program doctors, nurses and nurse practitioners
meet with patients from across the region
and country, and even do international
consultations that use early phase cancer
drugs, including those for brain tumors.
“This year the program participated in
about 25 studies and several others are in
the pipeline,” Dr. Neville said. “Some trials
are specifically for brain tumors and some
trials are for all solid tumors with the intention
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Experimental Therapeutics

Building on the hospital’s internationally recognized
expertise in clinical pharmacology, Experimental
Therapeutics serves as the clinical pharmacology core
for the Pediatric Oncology Experimental Therapeutics
Investigators’ Consortium and the Neuroblastoma
Medulloblastoma Treatment Research Consortium.
Treating a child, while minimizing toxic effects on
development, growth or function, and maintaining
quality of life is one of the program’s main objectives.

“The end goal is to find better ways that treatments
can be translated for children while finding drug
companies that will manufacture them,” Dr. Neville
said.
Another challenge with pharmacology is how
different children metabolize drugs. Some drugs can
affect growth and there can be more toxic effects
when children are given brain tumor drugs than for
adults because of their developing brains.
“I’m always saying this, but children really aren’t small
adults. It’s like treating two different populations.”

sympathy for other children and families because
their own child is not likely to survive.”
Seeing how patients’ families give with grace and
gratefulness motivates Neville and her colleagues’
work.
“Our patients and their families inspire us to push
forward in our battle to find better treatments –
and better ways producing and delivering those
treatments – to help children not only here in our
region, but around the world.”

The program’s success lies in the selflessness of
families and patients who agree to participate, adds
Dr. Neville.
“They come for services at a time when things can
be pretty grim and they do it with empathy and
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Research
Parent Satisfaction in an Outpatient Bone
Marrow Transplant Clinic
Funder: Alex’s Lemonade Stand
PI: Nancy Shreve
Outpatient care of children who have received
a bone marrow transplant is complex and
challenging. During the post transplant recovery
period, complications often arise that affect
prognosis, require treatment decisions or changes
in interventions, and/or re-hospitalization. The
parents of these children have multiple stressors as
they take on new responsibilities of monitoring for
complications, administering complex medication
regimens and performing unfamiliar procedures.
Lengthy and frequent clinic visits can create additional
stressors as parents try to balance home and work
commitments. A better understanding of parents’
needs and concerns during this time is a first step
in understanding how to positively contribute to
their satisfaction with their outpatient bone marrow
transplant experience. For this two-part study,
researchers conducted focus groups to understand
parental perceptions of the process. This information
was then used to create a tool that is being tested as
a measurement of satisfaction.

Effects of Intrathecal Methotrexate on
Folate Metabolism in the Cerebrospinal
Fluid of Children with Acute Lymphoblastic
Leukemia
Funder: Children’s Mercy Hospital’s Katherine
Berry Richardson Grant
PI: Keith August, MD
Chemotherapy given into the cerebrospinal fluid (CSF)
is an important part of therapy for patients diagnosed
with acute lymphoblastic leukemia (ALL) and nonHodgkin’s lymphoma (NHL). It helps to prevent a
relapse in the central nervous system. One medicine
commonly used for this purpose, methotrexate,
sometimes can have long-term effects that include
subtle changes in behavior and intelligence. It is not
well understood how giving methotrexate into the
CSF causes these symptoms and what other factors
may put patients at risk for side effects. How the drug
affects folate levels is one possible key. Researchers
are studying the CSF before and after methotrexate is
given to learn more about the causes of neurologic
side effects associated with methotrexate.
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Elongation Factor Protein in ALL

Pediatric Formulation of Chemotherapy

Funder: Midwest Cancer Alliance Partners
Advisory Board Funding

Funder: Midwest Cancer Alliance Partner’s
Advisory Board Funding

PI: Erin Guest, MD

PI: Kathleen Neville, MD

In collaboration with researchers at
The Stowers Institute

In collaboration with researchers at The
University of Kansas

The identification and development of effective
treatments for malignancies requires a thorough
understanding of the basic mechanisms of how
cancer develops. Researchers are doing this study
to see how proteins and genes interact inside of
leukemia cells. We think this will help us better
understand how leukemia develops. This study
will look for differences in proteins and genes
inside of leukemia cells in blood and/or bone
marrow, compared to healthy white blood cells.
Understanding these differences may help us find
better treatments for leukemia.

Many of the drugs used to treat children with cancer
come in forms that are not always child friendly. For
children who cannot swallow pills or capsules, this
creates issues. Through the years, doctors have
tried things like crushing and mixing these drugs to
get them in a form children can take. Research is
lacking to show that these methods are as useful
as the original form. Researchers in this study are
looking at how we can create child friendly versions of
chemotherapy drugs that we know are as effective as
the originally available commercial version.

Immunotherapy for GD2 Positive Tumors

Bridging the Gap

Funder: Midwest Cancer Alliance Partner’s
Advisory Board Funding

Funder: Midwest Cancer Alliance Partner’s
Advisory Board Funding

PI: Doug Myers, MD and Joy Fulbright, MD

PI: Sripriya Raman, MD

In collaboration with KU and Baylor College of
Medicine

In collaboration with KU

As tumors of neuroectodermal origin, the cancers
neuroblastoma and melanoma express cell
surface proteins not found on most tissues in the
human body. These proteins are of interest to
physicians as potential targets for tumor specific
immunotherapeutics. Both neuroblastoma and
melanoma have the surface protein called GD2.
Researchers in this study are growing cells with the
ability to recognize GD2 on cancer cells and kill it. In
the laboratory, we have found that T-cells that are
trained to recognize common viruses can stay in the
blood stream for many years. By joining the anti-GD2
antibody to T-cells that recognize and kill viruses, our
researchers believe that we will also be able to make
a cell that can last a long time in the body, provide
protection from viruses and recognize and kill cancer
cells.

providers to improve that knowledge, and evaluate
performance improvement strategies among
selected clinical sites. The program will also enable
primary care providers and subspecialists to develop
a network and collaborate more effectively in caring
for childhood cancer survivors.

The improvements in the treatment of childhood
cancer have led to an increased number of childhood
cancer survivors in the United States. Pediatric and
adult survivors of childhood cancer are at risk for late
effects or health problems that can present and/or
persist several years after the completion of treatment
and potentially affect any organ system in the body.
The need for long-term follow-up care of childhood
cancer survivors has been well established and
guidelines now exist to help providers monitor for
late effects of treatment. However, there continues to
be a knowledge gap among health care providers
in several topics related to monitoring and early
diagnosis of long-term effects of cancer treatment.
The goals of this project are to assess health care
providers’ knowledge of the unique needs of
childhood cancer survivors, develop a face-to-face
meeting and web-based educational series with
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